Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>CSI announced 19 ADDs and 19 DELETEs effective 15 Jun 2026, the largest cycle in our four-cycle reference set.</li>
<li>We reviewed rebalance stocks against four prior CSI 300 cycles and the completed pre-announcement setup.</li>
<li>The prior forecast captured the four strongest ADDs and six of the seven weakest DELETEs, with misses mainly in buffer-zone ADDs and retained-risk DELETEs.</li>
</ul>


CSI announced 19 ADDs and 19 DELETEs effective 15 Jun 2026, the largest cycle in our four-cycle reference set.
We reviewed rebalance stocks against four prior CSI 300 cycles and the completed pre-announcement setup.
The prior forecast captured the four strongest ADDs and six of the seven weakest DELETEs, with misses mainly in buffer-zone ADDs and retained-risk DELETEs.


Shanghai Electric Group Company (601727 CH)

Hangzhou Tigermed Consulting (A) (300347 CH)

Xinjiang Goldwind Science & Technology (002202 CH)

Beijing Tiantan Biological Products (600161 CH)

Beijing New Building Materials (000786 CH)

China Tungsten And Hightech Ma (000657 CH)

Wuxi Lead Intelligent Equipmen (300450 CH)

Shanghai RAAS Blood Products C (002252 CH)

Verisilicon Microelectronics S (688521 CH)

CSI 300 June 2026 Rebalance: Post-Announcement Positioning

Shengyi Electronics

CSI 300 June 2026 Rebalance: Post-Announcement Positioning